Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2006.
Business Overview: Greatbatch is a leading developer and manufacturer of batteries, capacitors, feedthroughs, and enclosures for implantable medical devices (IMC segment) and high-performance commercial power sources (ECP segment). The company operates on a 52/53-week fiscal year.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2006 |
Three Months Ended July 1, 2005 |
Six Months Ended June 30, 2006 |
Six Months Ended July 1, 2005 |
|---|---|---|---|---|
| Sales | $70,598 | $63,524 | $138,705 | $119,882 |
| Gross Profit | $26,777 | $24,161 | $54,411 | $43,990 |
| Gross Margin | 37.9% | 38.0% | 39.2% | 36.7% |
| Operating Income | $7,127 | $8,022 | $17,179 | $14,296 |
| Operating Margin | 10.1% | 12.6% | 12.4% | 11.9% |
| Net Income | $4,843 | $5,280 | $11,493 | $9,283 |
| Diluted EPS | $0.21 | $0.23 | $0.50 | $0.42 |
| Cash from Operations (6mo) | $8,265 (2006) vs $13,983 (2005) | |||
| Working Capital | $177.4 million (as of June 30, 2006) | |||
| Long-Term Debt | $170.0 million (Convertible Subordinated Notes) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 11% in Q2 and 16% in the first six months of 2006 compared to the prior year. The IMC segment grew 9% (Q2) and 14% (6mo), while the ECP segment grew 24% in both periods, driven by oil and gas exploration demand.
- Profitability Pressure: Despite revenue growth, Q2 operating income decreased 11% year-over-year. Operating margin declined 2.5 percentage points in Q2 primarily due to increased R&D spending and the adoption of SFAS No. 123(R) for stock-based compensation.
- Stock-Based Compensation: The adoption of SFAS No. 123(R) in fiscal 2006 resulted in an incremental expense of $0.9 million for Q2 and $1.9 million for the six-month period, reducing net income and EPS.
- Cash Flow: Operating cash flow decreased by $5.7 million in the first six months of 2006 compared to 2005, driven by increased inventory safety stocks, higher accounts receivable, and payments of accrued incentive compensation.
Guidance, Outlook, and Risks
- Outlook: Management expects operating margins to improve to 20% or better in the future as facility consolidations are completed and Tijuana facility utilization improves. R&D costs are expected to remain between 9% and 9.5% of sales for the remainder of 2006.
- Capital Expenditures: Expected to range between $22.0 million and $27.0 million for 2006, with $5.0 to $7.0 million attributed to the Tijuana facility build-out.
- Restructuring: Significant consolidation efforts are ongoing (Alden, Carson City, Columbia, and Tijuana facilities). Total estimated costs for these initiatives range from $6.6 million to $8.3 million. Annual cost savings of $5.0 to $6.0 million are anticipated upon completion.
- Risks:
- Customer Concentration: Three customers (Boston Scientific, St. Jude Medical, Medtronic) accounted for approximately 66% of total sales in the first half of 2006.
- Legal Proceedings: An arbitration process has been initiated regarding a settlement agreement with a developer of an implantable drug delivery device; potential loss cannot be reasonably estimated.
- Accounting Changes: The company is evaluating the impact of FIN No. 48 (Accounting for Uncertainty in Income Taxes), effective in fiscal 2007.
Investor Verification Checklist
- Customer Concentration: Verify the stability of relationships with the top three customers representing 66% of revenue.
- Restructuring Costs: Monitor the completion of facility consolidations (specifically Tijuana and Columbia) to ensure projected cost savings of $5.0–$6.0 million are realized.
- Stock-Based Compensation: Assess the ongoing impact of SFAS No. 123(R) on future earnings, noting $6.7 million of unrecognized compensation cost remains.
- Legal Contingency: Track the outcome of the arbitration regarding the implantable drug delivery device settlement.
- Inventory Levels: Review inventory build-up trends, which contributed to a $6.4 million cash outflow in the first six months of 2006.